dc.contributor
Institut Català de la Salut
dc.contributor
[Boutitah-Benyaich I, Eixarch H, Villacieros-Álvarez J, Hervera A, Cobo-Calvo Á, Montalban X] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, Spain. [Espejo C] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Boutitah-Benyaich, Imane
dc.contributor.author
Eixarch, Herena
dc.contributor.author
Villacieros-Álvarez, Javier
dc.contributor.author
Hervera Abad, Arnau
dc.contributor.author
Cobo-Calvo, Alvaro
dc.contributor.author
Montalban, Xavier
dc.contributor.author
Espejo, Carmen
dc.date.accessioned
2026-03-21T07:14:46Z
dc.date.available
2026-03-21T07:14:46Z
dc.date.issued
2026-03-20T11:24:46Z
dc.date.issued
2026-03-20T11:24:46Z
dc.date.issued
2025-10-02
dc.identifier
Boutitah-Benyaich I, Eixarch H, Villacieros-Álvarez J, Hervera A, Cobo-Calvo Á, Montalban X, et al. Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Ther. 2025 Oct 2;10:324.
dc.identifier
http://hdl.handle.net/11351/14367
dc.identifier
10.1038/s41392-025-02415-4
dc.identifier
001585285900003
dc.identifier.uri
https://hdl.handle.net/11351/14367
dc.description.abstract
Multiple sclerosis; Molecular pathogenesis; Therapeutic intervention
dc.description.abstract
Esclerosi múltiple; Patogènesi molecular; Intervenció terapèutica
dc.description.abstract
Esclerosis múltiple: Patogénesis molecular; Intervención terapéutica
dc.description.abstract
Multiple sclerosis is a chronic immune-mediated disorder of the central nervous system characterized by demyelination, axonal loss, and neuroinflammation, culminating in progressive neurological disability. Despite significant advances in understanding its immunopathogenesis, current immunotherapies remain limited in their ability to halt disease progression, making multiple sclerosis incurable and highlighting the critical need for novel therapeutic strategies. Antigen-specific immunotherapy represents a groundbreaking approach that aims to restore immune tolerance to myelin-derived antigens while preserving the protective functions of the immune system. Unlike broad immunosuppressive strategies, antigen-specific immunotherapy offers the potential for highly targeted modulation of pathogenic immune responses, reducing off-target effects and enhancing safety profiles. Over the last two decades, preclinical studies and clinical trials have explored diverse antigen-specific immunotherapy modalities, ranging from peptide-based vaccines to nanoparticle platforms, each aimed at achieving durable tolerance in multiple sclerosis. This review provides a comprehensive overview of multiple sclerosis, covering its etiology, clinical features, pathogenesis, pathology, and current therapeutic approaches. Thus, it delves into the current state of antigen-specific immunotherapy research, critically examining its successes and limitations while addressing the translational challenges that must be overcome to realize its therapeutic potential. By integrating insights from immunology, biotechnology, and translational medicine, we propose directions for advancing antigen-specific approaches in the quest for transformative multiple sclerosis therapies.
dc.description.abstract
This project has received funding from the MCIN/AEI/10.13039/501100011033 and the European Union-NextGenerationEU/PRTR through the CPP2021-008475 project. This work was also supported by the “Agència de Gestió d’Ajuts Universitaris i de Recerca” (AGAUR; Generalitat de Catalunya) through Consolidated Research Groups 2021SGR00782.
dc.format
application/pdf
dc.publisher
Springer Nature
dc.relation
Signal Transduction and Targeted Therapy;10
dc.relation
https://doi.org/10.1038/s41392-025-02415-4
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Esclerosi múltiple - Patogènesi
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::/therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::/terapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.title
Multiple sclerosis: molecular pathogenesis and therapeutic intervention
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion